EZH2 mutational status predicts poor survival in myelofibrosis. - Wikidata - awgldk - TriplyDB

EZH2 mutational status predicts poor survival in myelofibrosis.

EZH2 mutational status predicts poor survival in myelofibrosis.

http://www.wikidata.org/entity/Q54560112

about

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and Opportunities EZH2 in normal hematopoiesis and hematological malignancies Genetics of myeloproliferative neoplasms Chromatin targeting drugs in cancer and immunity Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Myeloid neoplasias: what molecular analyses are telling us Immunomodulatory agents in myelofibrosis.Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.EZH2 in normal and malignant hematopoiesis.JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.CD133 marks a stem cell population that drives human primary myelofibrosis.Polycomb repressive complex 2 is required for MLL-AF9 leukemia A complex Polycomb issue: the two faces of EZH2 in cancer.One thousand patients with primary myelofibrosis: the mayo clinic experience.Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Perspectives and future directions for epigenetics in hematology.Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.The future of epigenetic therapy in solid tumours--lessons from the past.Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis Epigenetics of hematopoiesis and hematological malignancies.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Emerging targeted therapies in myelofibrosis.Myeloproliferative neoplasm animal models Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms.Epigenetic alterations in hematopoietic malignancies.Molecular biology of Philadelphia-negative myeloproliferative neoplasms The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.

P2860

Q26738514-88ABC201-FF00-42C6-A55D-2BF314A69EE2 Q26744506-0EFE9966-FFA3-4957-A6EA-AAF853701E46 Q26779821-3EA1BDB2-E8AD-4C79-84BD-8DC6687C8007 Q26823651-4C5BC8F1-53E1-43F7-B9D6-AD902D7F8A32 Q26999888-5A33CB42-F847-499E-8344-E45EA3FEC4DA Q27681087-7F6148F2-89B3-4FD1-B794-3FBB75A4FCAC Q29147503-6AD4CDF6-606A-41C2-B7E9-D5990E05D81E Q30313615-EC8BFCBA-98E5-484F-B434-16A1FA5D3F84 Q33354547-1CC7F08D-4529-45E2-BDE6-E2F53CC23BEA Q33401615-12FCEC88-0E44-4E34-9622-8152644413C3 Q33558154-9108959F-2996-4F51-B220-68D8A60F9205 Q34037065-D76C4CBE-F6A2-4EAF-B1E5-FC7125CB69E6 Q34247430-65AE44A1-7BB1-4654-B410-7B8915DB293D Q34302770-9AAF86AA-24A1-4EFA-ADCB-E285D76CAAD6 Q34375614-5379FEE1-75DB-4229-A061-A04845557D2E Q34652224-E0D4CAF4-66E5-46EC-9ACE-C0B3E6CDF743 Q35669866-FD7613C1-ADE6-4196-974B-DC876C023A6C Q35882496-D06427AF-2E5D-4516-95A0-97F8EDB817C2 Q35914892-D69A602B-73DB-4C9F-A882-CB1CCCE37660 Q36512816-741D5A48-619D-412D-A5FC-40A932A8726B Q36682938-70A4967E-8846-45F3-98FC-3249D619140B Q36782943-921D378A-62FD-417E-9EB3-09CB6CDE0E79 Q36962664-D5C72C12-D248-4B24-822A-011E31A57718 Q37058122-987CD2F9-C932-4324-8BD0-AB224184BABA Q37061554-3E2A841B-FFCF-49D4-BF3F-FEF949564831 Q37178978-9885D44F-038D-4726-80C4-58C893B99D66 Q37343797-BED257F8-ADCB-49D7-8292-3F9758C83A8C Q37555785-736D4B37-4F68-455F-A80B-095FBF2C7E3E Q37956603-BA0A7FA1-5335-47EC-A7B9-7374EF0204D3 Q37968529-87D4863F-6F94-4A33-97CC-60C569154CFB Q37995804-EDEEE861-43E5-4621-A54E-8BCE648D39F2 Q37998574-98C0F7D8-8C8B-4F3B-837B-F96B63FE0ED7 Q38014534-4BA8C23E-CEE6-43AE-B4E3-5C4605A29C0A Q38018908-E0E87565-020E-484C-921A-3DE88007D29A Q38025160-C39650DF-F92E-4A1D-BA56-096C814DBCED Q38046320-88E25F51-33F9-4DF8-A78F-2E464BC5F60D Q38046648-D7870AA5-614B-47ED-8C3B-FF22E02ABAB2 Q38046794-5B9D7F8F-FD13-496C-9C28-B4C2CC2FAF43 Q38050756-BB424A38-5F22-4A5B-B3E6-72749F37C39C Q38059391-2485C134-D7BA-4EE4-A041-D6E2884307F5

P2860

EZH2 mutational status predicts poor survival in myelofibrosis.

http://www.wikidata.org/entity/Q54560112

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

EZH2 mutational status predicts poor survival in myelofibrosis.

@en

EZH2 mutational status predicts poor survival in myelofibrosis.

@nl

type

label

EZH2 mutational status predicts poor survival in myelofibrosis.

@en

EZH2 mutational status predicts poor survival in myelofibrosis.

@nl

prefLabel

EZH2 mutational status predicts poor survival in myelofibrosis.

@en

EZH2 mutational status predicts poor survival in myelofibrosis.

@nl

P1433

Q54560112-78080F6B-6FFA-4ACC-A1DF-2D043DDAD515

P1476

Q54560112-A05E0955-6DA6-4578-B129-3ED0B1B50DF3

P2093

Q54560112-0388B1A3-49D2-491F-9869-27A8A978D85E

Q54560112-14BB40E0-90B8-4DB7-A1A0-4F7A947E8B83

Q54560112-3F723F87-AFD6-4C1E-AC73-1FDEA47FC552

Q54560112-4B45B79B-374A-42A6-A160-921BB87DBF84

Q54560112-4DB45A37-AA8D-4588-82BB-9EDA44AC8914

Q54560112-4E70E7B4-FE9A-4DB2-A545-4F4875642617

Q54560112-5E91F500-5E2C-4097-BE04-1383DA4C32C1

Q54560112-9509F1E2-D050-4AE5-A628-F6B2EEB93174

Q54560112-9FEB7E87-9D16-4D54-882E-D6E94ECD3290

Q54560112-A480C47A-6176-4554-9637-59A070CCBC3F

P304

Q54560112-B226E51F-E3EA-4C92-849D-693F26AB7760

P31

Q54560112-5827DD6D-CBB2-4B13-BE43-BABC958361D8

P356

Q54560112-A4BF30E7-BBAF-45DF-B657-244EB2B798BB

P407

Q54560112-9861DA16-7F39-4279-B87D-162C6C561CA7

P433

Q54560112-DCA03B0A-36BE-4832-9CCA-FF1B078EDD83

P478

Q54560112-8D5C54C5-60ED-42C0-8845-08865336F87E

P50

Q54560112-275EF0C0-F75C-49EF-B7C0-5B0E9B7616A1

Q54560112-5D1B60BB-1A33-445F-A392-D040F1BD1AFA

Q54560112-78E06AB8-8D34-4E5B-A3A1-F2CCA34D44B7

Q54560112-98034095-2168-4BE0-AE7F-B0E7E650D912

P577

Q54560112-E6F8C421-AFBD-4585-8534-092F20B9BDAA

P698

Q54560112-D6F9C1B3-AEA4-4234-AA85-9AED6F69FF19

P356

BLOOD-2011-06-363424

P1433

P1476

EZH2 mutational status predicts poor survival in myelofibrosis

@en

P2093

Alessandro M Vannucchi

http://www.w3.org/2001/XMLSchema#string

Amy V Jones

http://www.w3.org/2001/XMLSchema#string

Andreas Reiter

http://www.w3.org/2001/XMLSchema#string

Andrew Duncombe

http://www.w3.org/2001/XMLSchema#string

Claire Hidalgo-Curtis

http://www.w3.org/2001/XMLSchema#string

Flavia Biamonte

http://www.w3.org/2001/XMLSchema#string

Francisco Cervantes

http://www.w3.org/2001/XMLSchema#string

Giovanni Barosi

http://www.w3.org/2001/XMLSchema#string

Joannah Score

http://www.w3.org/2001/XMLSchema#string

Katerina Zoi

http://www.w3.org/2001/XMLSchema#string

P304

5227-5234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-06-363424

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Paola Guglielmelli

P577

2011-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21921040

http://www.w3.org/2001/XMLSchema#string